Trial Profile
A Placebo-controlled, Single Blind, Randomised, Phase I, First In Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered CiVi007 in Subjects With an Elevated LDL C Level
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Cepadacursen (Primary)
- Indications Hypercholesterolaemia
- Focus First in man; Therapeutic Use
- Sponsors CiVi Biopharma
- 18 Sep 2020 Status changed from active, no longer recruiting to completed.
- 26 Jun 2020 Planned End Date changed from 1 Apr 2020 to 30 Sep 2020.
- 26 Jun 2020 Planned primary completion date changed from 1 Jan 2020 to 30 Jul 2020.